Zulokast LC Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 histamine receptors, thereby alleviating symptoms such as sneezing, nasal congestion, runny nose, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema, making it beneficial in the management of asthma and allergic rhinitis. The synergistic action of these two agents offers comprehensive control of allergic symptoms by targeting multiple pathways in the inflammatory cascade. Zulokast LC is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma management to improve pulmonary function and reduce exacerbations. It is generally well-tolerated, with a low incidence of adverse effects such as headache, fatigue, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision, especially in pediatric and elderly populations. This combination therapy enhances patient compliance by reducing pill burden while providing effective symptom control.